Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS
暂无分享,去创建一个
[1] J. Pappenheimer,et al. Active transport of Diodrast and phenolsulfonphthalein from cerebrospinal fluid to blood. , 1961, The American journal of physiology.
[2] W H Oldendorf,et al. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. , 1971, The American journal of physiology.
[3] E. Bárány. Inhibition by hippurate and probenecid of in vitro uptake of iodipamide and o-iodohippurate. A composite uptake system for iodipamide in choroid plexus, kidney cortex and anterior uvea of several species. , 1972, Acta physiologica Scandinavica.
[4] E. Bárány. The liver-like anion transport system in rabbit kidney, uvea and choroid plexus. I. Selectivity of some inhibitors, direction of transport, possible physiological substrates. , 1973, Acta physiologica Scandinavica.
[5] H. Davson,et al. Transport of sulfate in the rabbit's brain , 1973 .
[6] D. Calne,et al. Penicillin transport from cerebrospinal fluid , 1976, Neurology.
[7] K D Pettigrew,et al. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.
[8] K. Pettigrew,et al. Drug entry into the brain , 1979, Brain Research.
[9] W. Pardridge,et al. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. , 1979, The Journal of clinical investigation.
[10] V A Levin,et al. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.
[11] G. Goldstein,et al. Polarity of the blood-brain barrier: Distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells , 1980, Brain Research.
[12] C. Patlak,et al. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. , 1981, The American journal of physiology.
[13] T. Tsuruo,et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.
[14] S. Adler,et al. Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. , 1983, The Journal of clinical investigation.
[15] S. Rapoport,et al. An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.
[16] M. Center,et al. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. , 1987, Biochemical and biophysical research communications.
[17] W. Pardridge,et al. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. , 1987, The Journal of biological chemistry.
[18] A. Leo,et al. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.
[19] R Griffiths,et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. , 1988, Journal of medicinal chemistry.
[20] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[21] W. Pardridge,et al. Transport of histone through the blood-brain barrier. , 1989, The Journal of pharmacology and experimental therapeutics.
[22] S. P. Gupta,et al. QSAR studies on drugs acting at the central nervous system , 1989 .
[23] Hugh Davson,et al. History of the Blood-Brain Barrier Concept , 1989 .
[24] M. Epstein,et al. Cotransport of sodium and chloride by the adult mammalian choroid plexus. , 1990, The American journal of physiology.
[25] W. Pardridge,et al. Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. , 1990, Endocrinology.
[26] W. Pardridge,et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.
[27] N. Kaplowitz,et al. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. , 1990, The Journal of clinical investigation.
[28] R. Deane,et al. Transport of Lead‐203 at the Blood‐Brain Barrier During Short Cerebrovascular Perfusion with Saline in the Rat , 1990, Journal of neurochemistry.
[29] W. Pardridge,et al. Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein , 1991, FEBS letters.
[30] N. Bleehen,et al. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A , 1991 .
[31] T. Terasaki,et al. Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier. , 1991, The Journal of pharmacology and experimental therapeutics.
[32] R. Starzyk,et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Terasaki,et al. In‐vivo Blood‐brain Barrier Transport of a Novel Adrenocorticotropic Hormone Analogue, Ebiratide, Demonstrated by Brain Microdialysis and Capillary Depletion Methods , 1992, The Journal of pharmacy and pharmacology.
[34] W. Pardridge,et al. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. , 1992, The Journal of pharmacology and experimental therapeutics.
[35] H. Vinters,et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Kansy,et al. Hydrogen-Bonding Capacity and Brain Penetration , 1992, Chimia (Basel).
[37] R. Conradi,et al. The relationship between peptide structure and transport across epithelial cell monolayers , 1992 .
[38] C. S. Patlak,et al. Secretion and Bulk Flow of Interstitial Fluid , 1992 .
[39] G M Cohen,et al. Quinone chemistry and toxicity. , 1992, Toxicology and applied pharmacology.
[40] U. Bickel,et al. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[41] A. Granholm,et al. Delivery of Trophic Factors to the Primate Brain , 1993, Experimental Neurology.
[42] P. Wigler,et al. Inhibition of the multidrug resistance efflux pump. , 1993, Biochimica et biophysica acta.
[43] W. Scheithauer,et al. Clinical trials of agents that reverse multidrug resistance. A literature review , 1993, Cancer.
[44] S. Lightman,et al. Transport into retina measured by short vascular perfusion in the rat. , 1993, The Journal of physiology.
[45] Michael H. Abraham,et al. Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .
[46] F. Bloom,et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. , 1993, Science.
[47] V. Hruby,et al. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[49] D. Hipfner,et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.
[50] W. Pardridge,et al. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. , 1994, The Journal of pharmacology and experimental therapeutics.
[51] Michael H. Abraham,et al. Physicochemical analysis of the factors governing distribution of solutes between blood and brain , 1994 .
[52] B. Lannes. Peptide drug delivery to the brain. Raven Press, Oxford (1991), 1 vol, 357 p. , 1994 .
[53] J. Kordower,et al. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Meier,et al. Expression cloning of a rat liver Na(+)-independent organic anion transporter. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[55] C R Ganellin,et al. Predicting the brain-penetrating capability of histaminergic compounds. , 1994, Drug design and discovery.
[56] Harpreet S. Chadha,et al. Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. , 1994, Journal of pharmaceutical sciences.
[57] F. Baas,et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[58] D. Keppler,et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. , 1994, The Journal of biological chemistry.
[59] R T Borchardt,et al. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. , 1995, The Journal of pharmacology and experimental therapeutics.
[60] U. Bickel,et al. In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. , 1995, Bioconjugate chemistry.
[61] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[62] W. Pardridge. Vector-mediated peptide drug delivery to the brain. , 1995, Advanced drug delivery reviews.
[63] J. Kreuter,et al. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.
[64] W. Pardridge,et al. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[65] U. Bickel. Antibody delivery through the blood-brain barrier. , 1995, Advanced drug delivery reviews.
[66] W. Pardridge,et al. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[67] P. Chou,et al. Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients. , 1995, Pediatric neurosurgery.
[68] Y. Rustum,et al. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. , 1996, The American journal of pathology.
[69] R. Evers,et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.
[70] Hugh Davson,et al. Physiology of the CSF and Blood-Brain Barriers , 1996 .
[71] W. Dalton,et al. Serum can inhibit reversal of multidrug resistance by chemosensitisers. , 1996, European journal of cancer.
[72] D. Keppler,et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. , 1996, Cancer research.
[73] Michał J. Markuszewski,et al. Brain/blood distribution described by a combination of partition coefficient and molecular mass , 1996 .
[74] W. Wels,et al. Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein , 1996, The Journal of Biological Chemistry.
[75] D. Keppler,et al. The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion. , 1996, Advances in enzyme regulation.
[76] W. Pardridge,et al. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. , 1996, The Journal of pharmacology and experimental therapeutics.
[77] K. Nakamura,et al. Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography. , 1996, Journal of medicinal chemistry.
[78] A. Granholm,et al. Systemic Administration of a Nerve Growth Factor Conjugate Reverses Age-Related Cognitive Dysfunction and Prevents Cholinergic Neuron Atrophy , 1996, The Journal of Neuroscience.
[79] S. Cole,et al. ATP-dependent 17-Estradiol 17-(-D-Glucuronide) Transport by Multidrug Resistance Protein (MRP) , 1996, The Journal of Biological Chemistry.
[80] R. Starzyk,et al. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies. , 1996, The Journal of pharmacology and experimental therapeutics.
[81] D. Scherman,et al. Functional Expression of P‐Glycoprotein in an Immortalised Cell Line of Rat Brain Endothelial Cells, RBE4 , 1996, Journal of neurochemistry.
[82] B. Zlokovic,et al. Evidence for the Existence of a Sodium-dependent Glutathione (GSH) Transporter , 1996, The Journal of Biological Chemistry.
[83] M. Kool,et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.
[84] D. Keppler,et al. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. , 1997, Advances in enzyme regulation.
[85] P. Meier,et al. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[86] W. Banks,et al. Acute modulation of active carrier-mediated brain-to-blood transport of corticotropin-releasing hormone. , 1997, The American journal of physiology.
[87] B. Sikic,et al. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein , 1997, Cancer Chemotherapy and Pharmacology.
[88] S. Morrison,et al. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. , 1997, Journal of immunology.
[89] W. Banks,et al. Selective, Physiological Transport of Insulin Across the Blood-Brain Barrier: Novel Demonstration by Species-Specific Radioimmunoassays , 1997, Peptides.
[90] U. Bickel,et al. Brain Microvascular and Astrocyte Localization of P‐Glycoprotein , 1997, Journal of neurochemistry.
[91] Y. Sai,et al. Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.
[92] Harpreet S. Chadha,et al. Molecular Factors Influencing Drug Transfer across the Blood‐Brain Barrier , 1997, The Journal of pharmacy and pharmacology.
[93] U. Bickel,et al. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[94] Antioxidant defense of the brain: a role for astrocytes. , 1997, Canadian journal of physiology and pharmacology.
[95] J. Beijnen,et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.
[96] W. Pardridge,et al. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. , 1997, The Journal of clinical investigation.
[97] T. Yamashita,et al. Cloning and Functional Expression of a Brain Peptide/Histidine Transporter* , 1997, The Journal of Biological Chemistry.
[98] H. Galla,et al. Evidence for an asymmetrical uptake of L-carnitine in the blood-brain barrier in vitro. , 1997, Biochemical and biophysical research communications.
[99] P. Magistretti,et al. Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[100] A. Smith,et al. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. , 1998, Journal of the National Cancer Institute.
[101] W Vaalburg,et al. Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography , 1998, British journal of pharmacology.
[102] Y. Sugiyama,et al. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. , 1998, The Journal of pharmacology and experimental therapeutics.
[103] D. Begley,et al. The effect of drug lipophilicity on P-glycoprotein-mediated colchicine efflux at the blood-brain barrier. , 1998, International journal of clinical pharmacology and therapeutics.
[104] D. A. Kharkevich,et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.
[105] R. Bergmann,et al. Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells , 1998, Journal of neurochemistry.
[106] R. Yokel,et al. Aluminum transport out of brain extracellular fluid is proton dependent and inhibited by mersalyl acid, suggesting mediation by the monocarboxylate transporter (MCT1). , 1998, Toxicology.
[107] W. Pardridge,et al. Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein. , 1998, The Journal of pharmacology and experimental therapeutics.
[108] T. Tsuruo,et al. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. , 1998, The Journal of pharmacology and experimental therapeutics.
[109] S. Goldstein,et al. IAM retention and blood brain barrier penetration , 1998 .
[110] J. Nezu,et al. Molecular and Functional Identification of Sodium Ion-dependent, High Affinity Human Carnitine Transporter OCTN2* , 1998, The Journal of Biological Chemistry.
[111] D. Miller,et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. , 1998, Biochemical and biophysical research communications.
[112] B. Sabel,et al. Nanoparticle technology for delivery of drugs across the blood-brain barrier. , 1998, Journal of pharmaceutical sciences.
[113] Y. Sai,et al. Design and Synthesis of Peptides Passing through the Blood-Brain Barrier , 1998 .
[114] Y. Sugiyama,et al. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[115] J. Barrio,et al. Effects of Large Neutral Amino Acid Concentrations on 6-[F-18]Fluoro-L-DOPA Kinetics , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[116] W. Pardridge,et al. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. , 1999, Bioconjugate chemistry.
[117] W. Pardridge,et al. Neuroprotection with noninvasive neurotrophin delivery to the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[118] G Pradal,et al. Electron microscopy study of intrahepatic ultrasmall superparamagnetic iron oxide kinetics in the rat. Relation with magnetic resonance imaging , 1999, Biology of the cell.
[119] J. Kreuter,et al. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[120] R. Löbenberg,et al. Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier in vivo and in vitro , 2001, Journal of drug targeting.
[121] G. Vassal,et al. Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting , 2002, Journal of Pharmacology and Experimental Therapeutics.
[122] R. Müller,et al. Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate , 2002, Journal of drug targeting.
[123] Patrick Couvreur,et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat , 2002, The European journal of neuroscience.
[124] F. Calon,et al. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. , 2003, Human gene therapy.
[125] G. Pasternak,et al. Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy , 2003, Journal of Pharmacology and Experimental Therapeutics.
[126] A. Sbarbati,et al. In Vitro and In Vivo Study of Solid Lipid Nanoparticles Loaded with Superparamagnetic Iron Oxide , 2003, Journal of drug targeting.
[127] T. Terasaki,et al. Absorptive-Mediated Endocytosis of an Adrenocorticotropic Hormone (ACTH) Analogue, Ebiratide, into the Blood–Brain Barrier: Studies with Monolayers of Primary Cultured Bovine Brain Capillary Endothelial Cells , 1992, Pharmaceutical Research.
[128] Akira Tsuji,et al. Carrier-Mediated Intestinal Transport of Drugs , 1996, Pharmaceutical Research.
[129] K. Geiger,et al. Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.
[130] Si-Shen Feng,et al. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. , 2004, Current medicinal chemistry.
[131] H. Okada,et al. Insulin Fragments as a Carrier for Peptide Delivery Across the Blood–Brain Barrier , 1994, Pharmaceutical Research.
[132] T. Terasaki,et al. In Vivo Transport of a Dynorphin-like Analgesic Peptide, E-2078, Through the Blood–Brain Barrier: An Application of Brain Microdialysis , 1991, Pharmaceutical Research.
[133] Alexander V Kabanov,et al. Nanogels for oligonucleotide delivery to the brain. , 2004, Bioconjugate chemistry.
[134] P. Timmermans,et al. Lipophilicity and brain disposition of clonidine and structurally related imidazolidines , 1977, Naunyn-Schmiedeberg's Archives of Pharmacology.
[135] J. Kreuter,et al. Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.
[136] I. Arias,et al. The biology of the P-glycoproteins , 2004, The Journal of Membrane Biology.
[137] W. Pardridge,et al. Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration , 1998, Pharmaceutical Research.
[138] D. A. Kharkevich,et al. Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.
[139] J. R. Kanwar. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. , 2005, Current medicinal chemistry.
[140] N. Savaraj,et al. Drug resistance in brain tumors , 2005, Journal of Neuro-Oncology.
[141] Sungho Jin,et al. Quantum Dot Applications to Neuroscience: New Tools for Probing Neurons and Glia , 2006, The Journal of Neuroscience.
[142] S. Miller,et al. Mechanisms of Immunopathology in Murine Models of Central Nervous System Demyelinating Disease1 , 2006, The Journal of Immunology.
[143] Gabriel A Silva,et al. Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. , 2007, Surgical neurology.
[144] Harpreet S. Chadha,et al. Applications of a Solvation Equation to Drug Transport Properties , 2008 .